Hilda Kroksmark1, Maj Vinberg1. 1. a Psychiatric Centre Copenhagen, Rigshospitalet, University Hospital of Copenhagen , Copenhagen , Denmark.
Abstract
BACKGROUND: S100B is a calcium-binding protein located in glial cells; it is regarded as a potential biomarker in affective disorders. AIM: To review the literature investigating the role of S100B in patients with affective disorders. METHOD: A systematic review of original English language studies investigating S100B in serum, cerebrospinal fluid, plasma and lymphocytes, in patients with affective disorders, was conducted. The literature search was conducted within the PubMed database. Effect sizes were calculated to adjust for systematic measurement effects. RESULTS: Twenty studies were included, with a total of 1292 participants. Of these, 398 patients had or have had depressive disorder, 301 patients had bipolar disorder and 593 were healthy controls. S100B levels in serum were consistently elevated in studies with statistically significant results which investigated acute affective episodes (comprising major depressive episode in major depressive disorder, and both manic and depressive episodes in patients with bipolar disorder), in comparison to healthy controls. There were few studies assessing S100B levels in cerebrospinal fluid, plasma or lymphocytes, and these had inconsistent results. CONCLUSION: The results indicated that elevated S100B levels might be associated with mood episodes in affective disorders. However, the role of S100B, and its possible impact in affective disorders, requires further investigation and at the present S100B does not have a role as clinically biomarker in affective disorder. Future longitudinal multicentre studies with larger transdiagnostic real life patient cohorts are warranted.
BACKGROUND:S100B is a calcium-binding protein located in glial cells; it is regarded as a potential biomarker in affective disorders. AIM: To review the literature investigating the role of S100B in patients with affective disorders. METHOD: A systematic review of original English language studies investigating S100B in serum, cerebrospinal fluid, plasma and lymphocytes, in patients with affective disorders, was conducted. The literature search was conducted within the PubMed database. Effect sizes were calculated to adjust for systematic measurement effects. RESULTS: Twenty studies were included, with a total of 1292 participants. Of these, 398 patients had or have had depressive disorder, 301 patients had bipolar disorder and 593 were healthy controls. S100B levels in serum were consistently elevated in studies with statistically significant results which investigated acute affective episodes (comprising major depressive episode in major depressive disorder, and both manic and depressive episodes in patients with bipolar disorder), in comparison to healthy controls. There were few studies assessing S100B levels in cerebrospinal fluid, plasma or lymphocytes, and these had inconsistent results. CONCLUSION: The results indicated that elevated S100B levels might be associated with mood episodes in affective disorders. However, the role of S100B, and its possible impact in affective disorders, requires further investigation and at the present S100B does not have a role as clinically biomarker in affective disorder. Future longitudinal multicentre studies with larger transdiagnostic real life patient cohorts are warranted.
Authors: Ricard Navinés; Giovanni Oriolo; Igor Horrillo; Myriam Cavero; Bruno Aouizerate; Martin Schaefer; Lucile Capuron; J Javier Meana; Rocio Martin-Santos Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678
Authors: Luana Ketlen Reis Leão; Leonardo Oliveira Bittencourt; Ana Carolina Alves Oliveira; Priscila Cunha Nascimento; Maria Karolina Martins Ferreira; Giza Hellen Nonato Miranda; Railson de Oliveira Ferreira; Luciana Eiró-Quirino; Bruna Puty; Aline Dionizio; Sabrina Carvalho Cartágenes; Marco Aurelio M Freire; Marília Afonso Rabelo Buzalaf; Maria Elena Crespo-Lopez; Cristiane Socorro Ferraz Maia; Rafael Rodrigues Lima Journal: Oxid Med Cell Longev Date: 2021-10-07 Impact factor: 6.543